Abselion has contributed to a new editorial in Drug Discovery & Development, developed in collaboration with the VIB Protein Core Facility.
The article brings together core facility experience and technology development perspectives, exploring how protein production and characterisation workflows can better support decision-making in antibody discovery.
Co-authored by Kevin Balcaen and Ruizhi Wang, the piece examines how laboratories are adapting workflows as the scale and complexity of biologics research continues to grow.
Read the full article: here on pages 117-121.
Abselion: Drug Discovery and Development, June-September 2026 © Pharma Press Global Intelligence